Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain ...

The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary ...

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high ...

A poll of experts revealed that few are utilizing talquetamab for patients with pretreated relapsed/refractory myeloma.

Managing Severe Symptoms and Disease Progression in the GVHD Journey ...

After a patient with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer experiences disease progression ...

Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma. Lifestyle preferences and baseline ...

The FDA approved zolbetuximab-clzb (Vyloy) plus fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with locally advanced unresectable or metastatic HER2-negative ...

Patients with breast cancer who are of childbearing age may face issues that are accentuated by their age, an expert explained. Younger patients with breast cancer have certain concerns such as ...